AstraZeneca PLC Files 6-K Report
Ticker: AZN · Form: 6-K · Filed: 2025-12-04T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, 6-k, foreign-issuer
Related Tickers: AZN
TL;DR
AZN filed a 6-K, standard foreign issuer report. Nothing new, just compliance.
AI Summary
AstraZeneca PLC filed a Form 6-K on December 4, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 20-F, which is standard for foreign private issuers. The company is located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
Why It Matters
This filing is a routine disclosure for foreign issuers like AstraZeneca, confirming their reporting status and providing updated corporate information to the SEC and investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing by a foreign issuer and does not contain new material financial or operational information.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- ZENECA GROUP PLC (company) — Former company name
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (location) — Company's business and mail address
FAQ
What type of report is AstraZeneca PLC filing?
AstraZeneca PLC is filing a Form 6-K, which is a Report of Foreign Issuer.
What is the filing date of this report?
The filing date is December 4, 2025.
Which form does AstraZeneca PLC indicate it files annual reports under?
AstraZeneca PLC indicates it files annual reports under Form 20-F.
What is AstraZeneca PLC's primary business classification according to the filing?
AstraZeneca PLC's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What is the company's former name?
The company's former name was ZENECA GROUP PLC, with a date of name change of April 22, 1993.
From the Filing
0001654954-25-013678.txt : 20251204 0001654954-25-013678.hdr.sgml : 20251204 20251204134833 ACCESSION NUMBER: 0001654954-25-013678 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251204 FILED AS OF DATE: 20251204 DATE AS OF CHANGE: 20251204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251548931 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a3053k.htm HOLDING(S) IN COMPANY a3053k FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of December 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Holding(s) in Company     TR-1: Standard form for notification of major holdings   1. Issuer Details   ISIN GB0009895292   Issuer Name ASTRAZENECA PLC   UK or Non-UK Issuer UK   2. Reason for Notification   An acquisition or disposal of voting rights   3. Details of person subject to the notification obligation   Name The Capital Group Companies, Inc.   City of registered office (if applicable) Los Angeles   Country of registered office (if applicable) USA   4. Details of the shareholder   Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above     City of registered office (if applicable)     Country of registered office (if applicable)     5. Date on which the threshold was crossed or reached   02-Dec-2025   6. Date on which Issuer notified   03-Dec-2025   7. Total positions of person(s) subject to the notification obligation    . % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached   4.973499   0.000000   4.973499   77125348   Position of previous notification (if applicable)   5.017815   0.000000   5.017815       8. Notified details of the resulting sit